This evening, we are highlighting the publication of antibody persistence data out to 6 months following the second dose of the Moderna COVID-19 Vaccine in NEJM . Read more: buff.ly/3wDvCjl

Continuing innovation in base editing from Beam's amazing scientists! This new technique used in our BEAM-102 program for direct correction of the sickle cell mutation. Beam Therapeutics

Meet the #BeamTeam’s Nicole M. Gaudelli at the The Wall Street Journal's Future Of Everything Festival May 11-13! Nicole is #growing our Gene Editing Technologies Team and this is a great opportunity learn about the #BeamTeam #DaretoBeam #WSJFUTURE lnkd.in/eBuxzyi

The "Super Moon" was recently photographed from the station. It is a spectacular sight from space no matter what phase the Moon is in. More pix... flic.kr/s/aHsmACtudT

CRISPR prime editing with ribonucleoprotein complexes in zebrafish and primary human cells go.nature.com/336sL4V

Really interesting piece on gene editing -- by Jason Mast Apellis, Beam team up to test base editing against the broad field of complement disorders endpts.com/apellis-teams-…

Today Beam Therapeutics and Apellis Pharma announced an exclusive five-year research collaboration focused on the use of Beam’s proprietary base editing technology to discover new treatments for complement-driven diseases #DaretoBeam #BeamTeam globenewswire.com/news-release/2…

Excited to share the news for this collaboration with Apellis Pharma using base editing to treat complement-driven diseases, in line with the potential of base editing to not only treat rare diseases caused by point mutations but also to modulate complex biological systems

This is good reminder Gene editing ≠ gene therapy Several lines of evidence suggest that gene editing (editing endogenous DNA without viral vectors) likely to be durable for lifetime Follow along

Gene editing is one of biotech's fastest-moving, hottest spaces in biotech I went inside the labs at some of the industry's leaders, like Beam and Verve, to learn what's driving the excitement: businessinsider.com/biotech-gene-e…

We are also sharing our first data on LNPs targeting beyond the liver: A new class of LNPs producing 40% mRNA expression in hematopoietic stem cells in mice at 1.0mpk, with potential application for in vivo treatment of sickle cell disease and other hematologic disorders.

Check out our most recent review in Molecular Therapy where we take a deep dive into the process of bringing promising gene editing technologies to patients. It was a joy to write this manuscript with my colleagues at Beam Therapeutics, Holly Rees and Alex Minella, & Alexis Komor Komor Lab.

Yesterday we reported that the FDA has granted a safe to proceed to clinical studies for the first base editing program for the treatment of sickle cell disease. The talent, dedication and passion of everyone at Beam has made this possible. Thank you team! globenewswire.com/news-release/2…

Our LNP Discovery team is growing! Connect with Cory Sago or visit our careers site to learn more about joining the #BeamTeam #DaretoBeam beamtx.com/careers/

A selfish Italian political class avoids disaster at the last minute on.ft.com/3IJx6Om

Almost half of US Covid-19 hospitalisations this winter could have been avoided if the country had matched the vaccination coverage of leading European countries, FT analysis has found on.ft.com/3g8Es1x

The new BA.2 subvariant of SARS-CoV-2 has been referred to as a “stealth” #Omicron variant because it is harder to track and detect using certain PCR tests. Learn more: bit.ly/3AFNZqD

I am thrilled to be leading Orbital Therapeutics in addition to my role as President at Beam. This is an exciting opportunity to fully realize the potential of RNA medicines.

Today we report in Nature Genetics a study led by the team of Jonathan Yen and Mitch Weiss St. Jude that characterizes Cas9 nuclease and adenine base editing strategies to induce fetal hemoglobin expression, clinical approaches to treat sickle-cell disease & beta-thalassemia. 1/10

Congratulations to Verve Therapeutics for the first human data with an in vivo base editor, VERVE-101 targeting PCSK9 for cardiovascular disease (CVD)! It’s a hugely important milestone for the field: ir.vervetx.com/news-releases/…